Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 48 studies | 55% ± 21% | |
fibroblast | 40 studies | 47% ± 21% | |
pericyte | 36 studies | 54% ± 22% | |
smooth muscle cell | 30 studies | 51% ± 16% | |
B cell | 25 studies | 29% ± 10% | |
endothelial cell of lymphatic vessel | 19 studies | 34% ± 11% | |
connective tissue cell | 19 studies | 49% ± 23% | |
capillary endothelial cell | 17 studies | 57% ± 15% | |
endothelial cell of artery | 15 studies | 69% ± 17% | |
memory B cell | 14 studies | 24% ± 7% | |
epithelial cell | 14 studies | 43% ± 22% | |
vein endothelial cell | 14 studies | 58% ± 16% | |
endothelial cell of vascular tree | 14 studies | 47% ± 21% | |
macrophage | 12 studies | 22% ± 6% | |
naive B cell | 12 studies | 26% ± 8% | |
myofibroblast cell | 12 studies | 56% ± 22% | |
regulatory T cell | 12 studies | 26% ± 16% | |
basal cell | 12 studies | 37% ± 23% | |
type I pneumocyte | 9 studies | 40% ± 14% | |
T cell | 8 studies | 35% ± 23% | |
goblet cell | 8 studies | 37% ± 8% | |
mesothelial cell | 8 studies | 50% ± 22% | |
CD4-positive, alpha-beta T cell | 7 studies | 33% ± 19% | |
ciliated cell | 7 studies | 40% ± 26% | |
CD8-positive, alpha-beta T cell | 7 studies | 31% ± 14% | |
type II pneumocyte | 6 studies | 28% ± 15% | |
progenitor cell | 6 studies | 50% ± 19% | |
renal alpha-intercalated cell | 6 studies | 49% ± 22% | |
conventional dendritic cell | 6 studies | 24% ± 6% | |
ionocyte | 5 studies | 55% ± 22% | |
monocyte | 5 studies | 22% ± 3% | |
abnormal cell | 5 studies | 33% ± 17% | |
astrocyte | 5 studies | 28% ± 7% | |
intestinal crypt stem cell | 5 studies | 31% ± 7% | |
gamma-delta T cell | 5 studies | 41% ± 22% | |
transit amplifying cell | 5 studies | 27% ± 7% | |
enterocyte | 5 studies | 26% ± 6% | |
precursor B cell | 5 studies | 40% ± 11% | |
glial cell | 5 studies | 35% ± 15% | |
Mueller cell | 5 studies | 32% ± 12% | |
glomerular endothelial cell | 4 studies | 65% ± 10% | |
natural killer cell | 4 studies | 32% ± 8% | |
pro-B cell | 4 studies | 45% ± 12% | |
club cell | 4 studies | 33% ± 18% | |
neuron | 4 studies | 53% ± 10% | |
adventitial cell | 4 studies | 43% ± 5% | |
endothelial cell of sinusoid | 4 studies | 51% ± 35% | |
enteroendocrine cell | 4 studies | 44% ± 12% | |
secretory cell | 4 studies | 53% ± 18% | |
neural crest cell | 3 studies | 30% ± 5% | |
extravillous trophoblast | 3 studies | 45% ± 18% | |
placental villous trophoblast | 3 studies | 24% ± 6% | |
Schwann cell | 3 studies | 78% ± 9% | |
immature B cell | 3 studies | 37% ± 5% | |
myeloid cell | 3 studies | 25% ± 9% | |
intraepithelial lymphocyte | 3 studies | 47% ± 18% | |
kidney loop of Henle epithelial cell | 3 studies | 18% ± 2% | |
germinal center B cell | 3 studies | 21% ± 4% | |
myoepithelial cell | 3 studies | 39% ± 15% | |
muscle cell | 3 studies | 41% ± 10% | |
leukocyte | 3 studies | 25% ± 6% | |
keratinocyte | 3 studies | 36% ± 9% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 14 studies | 31% ± 17% | |
intestine | 10 studies | 33% ± 13% | |
kidney | 7 studies | 33% ± 17% | |
heart | 5 studies | 25% ± 9% | |
uterus | 5 studies | 35% ± 7% | |
prostate | 4 studies | 22% ± 3% | |
skin | 4 studies | 36% ± 13% | |
breast | 4 studies | 31% ± 8% | |
pancreas | 3 studies | 18% ± 1% | |
placenta | 3 studies | 31% ± 10% | |
eye | 3 studies | 35% ± 8% | |
lymph node | 3 studies | 24% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 15222.83 | 653 / 653 | 98% | 314.11 | 594 / 605 |
intestine | 98% | 5295.80 | 950 / 966 | 92% | 158.59 | 486 / 527 |
bladder | 100% | 9616.24 | 21 / 21 | 90% | 185.12 | 456 / 504 |
stomach | 97% | 5058.41 | 349 / 359 | 90% | 115.64 | 258 / 286 |
prostate | 99% | 8245.87 | 242 / 245 | 88% | 128.46 | 440 / 502 |
uterus | 97% | 5420.91 | 165 / 170 | 88% | 197.78 | 406 / 459 |
lung | 98% | 7171.94 | 566 / 578 | 87% | 103.37 | 1005 / 1155 |
kidney | 93% | 5375.36 | 83 / 89 | 91% | 195.59 | 821 / 901 |
breast | 98% | 7637.65 | 450 / 459 | 83% | 80.73 | 923 / 1118 |
esophagus | 93% | 6235.09 | 1338 / 1445 | 87% | 85.79 | 159 / 183 |
adrenal gland | 91% | 3470.20 | 235 / 258 | 76% | 98.45 | 175 / 230 |
ovary | 97% | 7104.22 | 174 / 180 | 57% | 55.10 | 246 / 430 |
pancreas | 57% | 1436.97 | 186 / 328 | 96% | 137.52 | 171 / 178 |
brain | 49% | 1383.55 | 1306 / 2642 | 99% | 591.75 | 697 / 705 |
skin | 94% | 5074.84 | 1703 / 1809 | 38% | 54.19 | 179 / 472 |
ureter | 0% | 0 | 0 / 0 | 100% | 206.15 | 1 / 1 |
blood vessel | 100% | 16580.59 | 1334 / 1335 | 0% | 0 | 0 / 0 |
adipose | 99% | 8139.09 | 1197 / 1204 | 0% | 0 | 0 / 0 |
heart | 99% | 7205.50 | 855 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 113.44 | 28 / 29 |
spleen | 90% | 2843.94 | 216 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 89% | 127.82 | 40 / 45 |
liver | 26% | 637.65 | 59 / 226 | 40% | 34.36 | 163 / 406 |
muscle | 49% | 1128.13 | 391 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 20% | 1015.99 | 183 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 9% | 4.25 | 7 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0042476 | Biological process | odontogenesis |
GO_0010629 | Biological process | negative regulation of gene expression |
GO_0030855 | Biological process | epithelial cell differentiation |
GO_0007507 | Biological process | heart development |
GO_0045662 | Biological process | negative regulation of myoblast differentiation |
GO_0001656 | Biological process | metanephros development |
GO_0010628 | Biological process | positive regulation of gene expression |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0043433 | Biological process | negative regulation of DNA-binding transcription factor activity |
GO_0072750 | Biological process | cellular response to leptomycin B |
GO_0032922 | Biological process | circadian regulation of gene expression |
GO_0030182 | Biological process | neuron differentiation |
GO_0030154 | Biological process | cell differentiation |
GO_0045668 | Biological process | negative regulation of osteoblast differentiation |
GO_0007517 | Biological process | muscle organ development |
GO_0007417 | Biological process | central nervous system development |
GO_0006275 | Biological process | regulation of DNA replication |
GO_0043065 | Biological process | positive regulation of apoptotic process |
GO_0030903 | Biological process | notochord development |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0043425 | Molecular function | bHLH transcription factor binding |
GO_1901707 | Molecular function | leptomycin B binding |
GO_0019904 | Molecular function | protein domain specific binding |
GO_0140416 | Molecular function | transcription regulator inhibitor activity |
GO_0140110 | Molecular function | transcription regulator activity |
GO_0046983 | Molecular function | protein dimerization activity |
GO_0005515 | Molecular function | protein binding |
Gene name | ID3 |
Protein name | DNA-binding protein inhibitor ID-3 (Class B basic helix-loop-helix protein 25) (bHLHb25) (Helix-loop-helix protein HEIR-1) (ID-like protein inhibitor HLH 1R21) (Inhibitor of DNA binding 3) (Inhibitor of differentiation 3) |
Synonyms | 1R21 BHLHB25 HEIR1 |
Description | FUNCTION: Transcriptional regulator (lacking a basic DNA binding domain) which negatively regulates the basic helix-loop-helix (bHLH) transcription factors by forming heterodimers and inhibiting their DNA binding and transcriptional activity. Implicated in regulating a variety of cellular processes, including cellular growth, senescence, differentiation, apoptosis, angiogenesis, and neoplastic transformation. Involved in myogenesis by inhibiting skeletal muscle and cardiac myocyte differentiation and promoting muscle precursor cells proliferation. Inhibits the binding of E2A-containing protein complexes to muscle creatine kinase E-box enhancer. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-BMAL1 heterodimer. . |
Accessions | Q02535 ENST00000374561.6 ENST00000634790.2 |